A Three-Drug Combination Cleared HIV From Baby Monkeys and Kept It Away for a Year

A single course of three combined therapies, started within three days of birth, left eight infant monkeys with no detectable HIV a year after treatment stopped. The study, led by Oregon Health & Science University and published August 10 in Nature Microbiology, does not prove the approach will work in human newborns. But the researchers behind it say the result surprised them enough to push straight toward early human trials.

KEY NUMBER
All eight infant macaques given the triple combination showed no detectable HIV a year after therapy stopped, even after researchers deliberately suppressed their immune systems to try to provoke a rebound.

What Happened

Researchers at OHSU's Oregon National Primate Research Center and the California National Primate Research Center infected newborn macaques with SHIV, a hybrid virus used to model HIV in monkeys, then treated eight of them with a three-part regimen inside 72 hours: standard antiretroviral drugs, broadly neutralizing antibodies, and leronlimab, an antibody that blocks the CCR5 protein HIV uses to enter immune cells. At 56 weeks, the team checked for HIV-specific immune cells and antibodies and found none. The animals had never mounted a response to a lingering infection. At 61 weeks, they deliberately wiped out CD8 immune cells, a stress test that brought the virus roaring back in untreated and two-drug control groups. In the triple-therapy animals, nothing returned. A tissue assay at necropsy found no trace of intact or defective virus in their immune cells.

Why It Matters

Every one of the three therapies had already been tried alone against HIV and failed to permanently clear it. That's why lead researcher Jonah Sacha didn't expect stacking them to work any better. Co-author Nancy Haigwood, who proposed combining leronlimab with the other two, called the outcome "a remarkable result." Antiretroviral therapy is already approved for people, and the neutralizing antibodies and leronlimab are each in separate human trials. The individual pieces aren't unfamiliar to regulators. What has not been tried is stacking all three inside the first days of a newborn's infection, the window this study targets.

How the Combination Works

The researchers describe the three drugs as attacking the virus from different angles: antiretroviral therapy slows how fast HIV copies itself, the neutralizing antibodies clear circulating virus particles from the blood, and leronlimab blocks the CCR5 doorway the virus needs to infect new cells. None of the three, alone, starves the virus of every route to persist. Together, applied before HIV can establish a hidden reservoir in long-lived immune cells, the combination appears to close off that escape route before it forms. Exactly why the combined effect is so much stronger than any single therapy remains unexplained. The team says untangling that mechanism is now a priority.

What Happens Next

Sacha says the antiretroviral and antibody components are already established enough in humans that the regimen could move toward early clinical trials without years of preliminary safety work. The first human tests are likely to target newly exposed adults rather than newborns, both because adult trials are logistically and ethically simpler and because a positive result there would strengthen the case for testing infants next. Researchers also want to establish how long after infection the regimen still works, since the current result only covers the first three days.

Takeaway

Every ingredient in this regimen had already failed on its own. That's the detail that makes the combination worth watching. Stacking three approved and experimental therapies before HIV can hide inside long-lived immune cells did something none of them could do separately. Researchers still can't fully explain why. That unexplained synergy, not the individual drugs, is what the next round of research needs to pin down before anyone can say whether this closes a door on newborn HIV or just narrows it.